We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why is a Beat Less Likely for Ameriprise (AMP) in Q2 Earnings?
Read MoreHide Full Article
Ameriprise Financial, Inc. (AMP - Free Report) is scheduled to report second-quarter 2019 results on Jul 24, after the market closes. While its earnings for the to-be-reported quarter are expected to grow year over year, revenues are likely to decline.
In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Results benefited from growth in assets under management (AUM) and assets under administration (AUA). However, lower revenues and rise in operating expenses were headwinds.
Ameriprise has an impressive earnings surprise history. Its earnings surpassed the Zacks Consensus Estimate in all of the trailing four quarters, the average beat being 3.3%.
However, activities of the company in the second quarter did not encourage analysts to revise earnings estimates upward. Thus, the Zacks Consensus Estimate for earnings of $4.00 for the to-be-reported quarter has remained unchanged over the past seven days. Nevertheless, the figure indicates 11.1% growth from the prior-year quarter’s reported number.
The consensus estimate for the company’s sales is pegged at $2.95 billion, which suggests nearly 7.8% decrease from the year-ago quarter’s reported figure.
Before we take a look at what our quantitative model predicts for the second quarter, let’s check the factors that are likely to influence results.
Factors to Influence Q2 Results
Ameriprise has been witnessing net outflows in the Asset Management segment over the past few years, which negatively impacted AUM and AUA to some extent. However, the Advice & Wealth Management segment is likely to record growth in assets in the second quarter, based on expectations of improved advisor productivity. Thus, total assets are likely to rise in the to-be-reported quarter.
Supported by expected increase in assets, the related fee is also likely to be positively impacted.
However, while the company’s initiatives to focus on cost management resulted in controlled general and administrative expenses, advertising campaign and technology upgrades will likely keep costs elevated.
Earnings Whispers
According to our quantitative model, chances of Ameriprise beating the Zacks Consensus Estimate in the second quarter are low. This is because it does not have the right combination of the two key ingredients — a positive Earnings ESP and Zacks Rank #3 (Hold) or better — to increase the odds of an earnings beat.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Ameriprise has an Earnings ESP of -2.00%.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
Stocks That Warrant a Look
Here are some finance stocks that you may want to consider as these have the right combination of elements to post an earnings beat this quarter, per our model.
T. Rowe Price Group, Inc. (TROW - Free Report) has an Earnings ESP of +0.33% and sports a Zacks Rank #1 (Strong Buy) at present. The company is expected to release results on Jul 24.
Ares Capital Corporation (ARCC - Free Report) is expected to release results on Jul 30. It presently has an Earnings ESP of +1.02% and a Zacks Rank #2 (Buy).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Why is a Beat Less Likely for Ameriprise (AMP) in Q2 Earnings?
Ameriprise Financial, Inc. (AMP - Free Report) is scheduled to report second-quarter 2019 results on Jul 24, after the market closes. While its earnings for the to-be-reported quarter are expected to grow year over year, revenues are likely to decline.
In the last reported quarter, the company’s earnings surpassed the Zacks Consensus Estimate. Results benefited from growth in assets under management (AUM) and assets under administration (AUA). However, lower revenues and rise in operating expenses were headwinds.
Ameriprise has an impressive earnings surprise history. Its earnings surpassed the Zacks Consensus Estimate in all of the trailing four quarters, the average beat being 3.3%.
Ameriprise Financial, Inc. Price and EPS Surprise
Ameriprise Financial, Inc. price-eps-surprise | Ameriprise Financial, Inc. Quote
However, activities of the company in the second quarter did not encourage analysts to revise earnings estimates upward. Thus, the Zacks Consensus Estimate for earnings of $4.00 for the to-be-reported quarter has remained unchanged over the past seven days. Nevertheless, the figure indicates 11.1% growth from the prior-year quarter’s reported number.
The consensus estimate for the company’s sales is pegged at $2.95 billion, which suggests nearly 7.8% decrease from the year-ago quarter’s reported figure.
Before we take a look at what our quantitative model predicts for the second quarter, let’s check the factors that are likely to influence results.
Factors to Influence Q2 Results
Ameriprise has been witnessing net outflows in the Asset Management segment over the past few years, which negatively impacted AUM and AUA to some extent. However, the Advice & Wealth Management segment is likely to record growth in assets in the second quarter, based on expectations of improved advisor productivity. Thus, total assets are likely to rise in the to-be-reported quarter.
Supported by expected increase in assets, the related fee is also likely to be positively impacted.
However, while the company’s initiatives to focus on cost management resulted in controlled general and administrative expenses, advertising campaign and technology upgrades will likely keep costs elevated.
Earnings Whispers
According to our quantitative model, chances of Ameriprise beating the Zacks Consensus Estimate in the second quarter are low. This is because it does not have the right combination of the two key ingredients — a positive Earnings ESP and Zacks Rank #3 (Hold) or better — to increase the odds of an earnings beat.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Ameriprise has an Earnings ESP of -2.00%.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
Stocks That Warrant a Look
Here are some finance stocks that you may want to consider as these have the right combination of elements to post an earnings beat this quarter, per our model.
T. Rowe Price Group, Inc. (TROW - Free Report) has an Earnings ESP of +0.33% and sports a Zacks Rank #1 (Strong Buy) at present. The company is expected to release results on Jul 24.
Franklin Resources, Inc. (BEN - Free Report) is slated to release results on Jul 30. It currently has an Earnings ESP of +0.13% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Ares Capital Corporation (ARCC - Free Report) is expected to release results on Jul 30. It presently has an Earnings ESP of +1.02% and a Zacks Rank #2 (Buy).
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>